Scholarlink

<p>The Bayer Data Generation and Observational Studies (DGOS) team has partnered longitudinally with a consistent advisor group (DGOS Council). The DGOS Council operates as an extension of the DGOS team, providing external strategic perspectives. Here, we describe Bayer’s engagement with the DGOS Council and how it contributes throughout a product’s lifecycle. We present the composition and organization of the DGOS Council, share case studies describing its relation to and impact across Bayer’s portfolio of products, and discuss bi-directional benefits to Bayer and DGOS Council members. We conclude with recommendations for best practices for an HEOR Peer Review Council model. Teaser. Bayer has partnered longitudinally with a group of strategic advisors. The relationship between Bayer and the advisors is described here as a consideration for best practice for evidence generation teams.&#xa0;</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Transforming Traditional Industry Advisory Boards Into Mutually Beneficial Strategic Think Tanks: A Peer Review Council Case Series and Best Practices

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月23日

查看全文
  • Todd Williamson,
  • John Fox,
  • Scott Ramsey,
  • Maria Martins-Lopes,
  • Kevin M. Pantalone,
  • C. Daniel Mullins,
  • Kenneth Schaecher,
  • Sean D. Sullivan

摘要

The Bayer Data Generation and Observational Studies (DGOS) team has partnered longitudinally with a consistent advisor group (DGOS Council). The DGOS Council operates as an extension of the DGOS team, providing external strategic perspectives. Here, we describe Bayer’s engagement with the DGOS Council and how it contributes throughout a product’s lifecycle. We present the composition and organization of the DGOS Council, share case studies describing its relation to and impact across Bayer’s portfolio of products, and discuss bi-directional benefits to Bayer and DGOS Council members. We conclude with recommendations for best practices for an HEOR Peer Review Council model. Teaser. Bayer has partnered longitudinally with a group of strategic advisors. The relationship between Bayer and the advisors is described here as a consideration for best practice for evidence generation teams.